Fulton Bank N.A. Invests $208,000 in argenx SE (NASDAQ:ARGX)

Fulton Bank N.A. purchased a new position in argenx SE (NASDAQ:ARGXGet Rating) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 549 shares of the company’s stock, valued at approximately $208,000.

A number of other large investors have also recently made changes to their positions in ARGX. Northern Trust Corp grew its stake in shares of argenx by 22.2% in the fourth quarter. Northern Trust Corp now owns 16,912 shares of the company’s stock worth $5,923,000 after acquiring an additional 3,067 shares during the period. Raymond James & Associates bought a new stake in argenx during the fourth quarter valued at approximately $1,329,000. BNP Paribas Arbitrage SA bought a new stake in argenx during the fourth quarter valued at approximately $535,000. HighTower Advisors LLC bought a new stake in argenx during the fourth quarter valued at approximately $203,000. Finally, Ensign Peak Advisors Inc grew its position in argenx by 96.5% during the fourth quarter. Ensign Peak Advisors Inc now owns 18,520 shares of the company’s stock valued at $6,485,000 after buying an additional 9,097 shares during the period. 59.75% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on ARGX shares. HC Wainwright boosted their target price on shares of argenx from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Friday, July 29th. JPMorgan Chase & Co. boosted their target price on shares of argenx from €390.00 ($397.96) to €430.00 ($438.78) and gave the company an “overweight” rating in a research report on Thursday, July 14th. Morgan Stanley upped their price target on shares of argenx from $375.00 to $401.00 and gave the stock an “overweight” rating in a research report on Friday, July 29th. Stifel Nicolaus upped their price target on shares of argenx from $460.00 to $471.00 in a research report on Thursday, July 28th. Finally, Robert W. Baird reiterated a “downgrade” rating on shares of argenx in a research report on Friday, July 29th. One analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $397.50.

argenx Trading Down 1.8 %

Shares of ARGX opened at $373.26 on Monday. The company’s fifty day simple moving average is $373.64 and its 200-day simple moving average is $338.56. The company has a market cap of $20.55 billion, a P/E ratio of -21.54 and a beta of 0.83. argenx SE has a twelve month low of $249.50 and a twelve month high of $403.77.

argenx (NASDAQ:ARGXGet Rating) last issued its earnings results on Thursday, July 28th. The company reported ($3.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.76) by $0.95. argenx had a negative net margin of 538.17% and a negative return on equity of 49.45%. The company had revenue of $85.18 million for the quarter, compared to analysts’ expectations of $40.05 million. Analysts predict that argenx SE will post -15.52 earnings per share for the current fiscal year.

argenx Company Profile

(Get Rating)

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study.

See Also

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenx SE (NASDAQ:ARGXGet Rating).

Institutional Ownership by Quarter for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.